Takeaway
- Prophylactic use of aspirin may delay development of preterm and term preeclampsia.
- Women with risk factors for preeclampsia may experience greater benefits.
Why this matters
- The mechanism for how aspirin prevents preeclampsia is unclear.
Key results
- The experimental model proves aspirin prevents both preterm and term preeclampsia, but high-risk patients differed from low-risk patients.
- In high-risk patients, the risk for preterm preeclampsia was reduced in women on aspirin (2.7% vs 7.1%).
- In low-risk patients, the use of prophylactic aspirin reduced the risk for term preeclampsia (3.6% vs 5.7%).
Study design
- Unplanned secondary subgroup analysis of data from the ASPRE trial, involving 13 hospitals investigating risks for and prevention of preeclampsia with aspirin.
- A model was developed and fitted to examine the hypothesis that aspirin causes a delay in gestational age at time of diagnosis of preeclampsia.
- Funding: Fetal Medicine Foundation and European Union 7th Framework Programme.
Limitations
- Model needs to be validated.
- Lack of power for preeclampsia at term.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionals